Fig. 12
Light-responsive diagnostic and therapeutic integrated platform for RA treatment and monitoring. A Schematic illustration of M@P-siRNAsT/I for PAI-guided RA therapy. B PAI of healthy and RA mice treated with saline, PBNPs, Lip-siRNAsT/I and M@P-siRNAsT/I for detecting the ability to target RA joint (MAP, maximum amplitude projection; B-scan, cross section image). C Forepaw PAI (B-scan) after 49 days of treatment to assess the degree of hypoxia (PA signals obtained at 725 nm and 800 nm wavelengths were used to construct oxygen saturation maps, rainbow shows the relative PA blood oxygen signal). Reproduced with permission [185]. Copyright 2022, PNAS. D Schematic diagram of the construction process of mZMI@HA nanoprobes and their high-sensitivity PersL imaging-guided RA therapy. E PersL images of healthy and RA mice after treated mZMI@HA at different time points. F PersL images of mice after complete treatment to assess efficacy. G Joint morphology and H micro-CT 3D reconstruction images of mice after treatment. I H&E (top) and Safranin-O (bottom) staining of ankle joints after treatment. (G1: normal mice, G2: RA model of PBS, G3: RA model of PBS with laser, G4: RA model of ICG with laser, G5: RA model of MTX, G6: RA model of mZMI@HA with laser.) Reproduced with permission [188]. Copyright 2023, Wiley-VCH